✦ LIBER ✦

Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer

✍ Scribed by S. Urien; P. Fumoleau; M. Campone; P. Kerbrat; J. Bonneterre; P. Fargeot; R. Deporte-Fety

Publisher: Springer
Year: 2003
Tongue: English
Weight: 457 KB
Volume: 52
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-003-0616-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I and pharmacokinetic study of o

A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer

✍ N. J. Meropol; Yousef M. Rustum; Nicholas J. Petrelli; Miguel Rodriguez-Bigas; C 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 286 KB

A phase 2 study of a fixed combination o

A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer

✍ Gabriel N. Hortobagyi; William Heim; Laura Hutchins; Edgardo Rivera; Bernard Mas 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 1 views

Pharmacokinetic and pharmacodynamic stud

Pharmacokinetic and pharmacodynamic study of IST-622, a novel synthetic derivative of chartreusin, by oral administration in a phase II study of patients with breast cancer

✍ Gyo Asai; Nobuyuki Yamamoto; Masakazu Toi; Eisei Shin; Kiyoshi Nishiyama; Tomohi 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 123 KB

Erythropoietin and granulocyte-macrophag

Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer

✍ M. Venturini; L. Del Mastro; Franco Testore; Marco Danova; Ornella Garrone; Clau 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 160 KB

Comparative open, randomized, cross-over

Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane® and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC)

✍ H. Rosing; W. W. Ten Bokkel Huinink; R. van Gijn; R. F. M. Rombouts; A. Bult; J. 📂 Article 📅 1999 🏛 Springer-Verlag 🌐 English ⚖ 795 KB